Zoll acquires Kyma Medical Technologies, expands into heart failure
Zoll acquired Kyma Medical Technologies, a Tel Aviv, Israel-based developer of technologies to measure early signs of congestive heart failure. Terms of the deal were not announced.
Kymia is developing a remote patient monitoring system that uses radio frequency-based technology to detect and monitor the level of fluid in the lungs and collects data on heart rate, respiration rate, activity and posture. The system then analyzes the information via an algorithm to determine vital signs trends in patients and sends a notification to the patients’ medical team if their condition deteriorates, according to a news release announcing the acquisition.
The system is not FDA-approved, although it is approved in Europe to monitor thoracic fluid content, ECG, heart rate, respiration rate, activity and posture.
Zoll specializes in developing medical devices and software for resuscitation and acute and emergency care. The company has products for defibrillation and monitoring, circulation and CPR feedback, data management, ventilation, fluid resuscitation and therapeutic temperature management.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.